Skip to contentM
MapLight Therapeutics, Inc.
M
MPLTMapLight Therapeutics, Inc. Released Mar 26, 2026, before the open
10-K filed Mar 26, 2026, 85 days after period end · 0001193125-26-125072
Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$79.55M-$79.55MderivedN/M vs Q4 2024
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
MapLight Therapeutics, Inc. · CIK 1770069 · Engraved from SEC EDGAR
N/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$83,379,000— Operating Cash Flowderived-$46,829,000N/M Free Cash Flowderived-$47,205,000N/M ended Dec 31, 2025 · filed Mar 26, 2026 · 85 d after period end
+6.0% from the close of Mar 25, 2026 to the close of Mar 26, 2026, the first after the release.
before the open$18.14$19.23 Mar 4Mar 26Apr 17